As #ASCO19 looms, a top analyst showers some love — and blockbuster status — on Amgen's KRAS killer
Amgen is feeling the love this morning.
Geoffrey Porges, a top biotech analyst at SVB Leerink known for his hard-hitting style, is putting the spotlight on their KRAS drug AMG510, projecting a peak sales potential of $2.3 billion while advising Amgen to keep this one for the home team.
With ASCO looming this weekend, there’s been a growing focus on KRAS, one of the toughest targets in oncology R&D. Amgen is a leader among a group of developers who have found a toehold on KRAS: G12C. And Porges believes that Amgen has a reasonable shot at making a drug that can conceivably work in lung, colorectal, pancreatic, and uterine cancer — which qualifies as a potential market master worth billions in sales.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,300+ biopharma pros reading Endpoints daily — and it's free.